Neuropathy, skin rash, and hyperglycemia are linked to improved PFS in patients treated with enfortumab vedotin for metastatic urothelial carcinoma. Patients experiencing these side effects had longer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results